- Report
- February 2024
- 175 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- December 2023
- 173 Pages
Global
From €2391EUR$2,500USD£2,049GBP
- Report
- February 2024
- 175 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- March 2024
- 200 Pages
Global
From €3968EUR$4,150USD£3,401GBP
- Report
- September 2023
- 138 Pages
Global
From €3046EUR$3,185USD£2,610GBP
€4351EUR$4,550USD£3,728GBP
- Report
- April 2023
- 500 Pages
Global
From €3108EUR$3,250USD£2,663GBP
- Report
- April 2023
- 111 Pages
Global
From €4088EUR$4,275USD£3,503GBP
€4542EUR$4,750USD£3,892GBP
- Report
- January 2024
- 70 Pages
North America
From €2376EUR$2,485USD£2,036GBP
€3395EUR$3,550USD£2,909GBP
- Report
- November 2022
- 154 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- November 2021
- 222 Pages
Global
From €2869EUR$3,000USD£2,458GBP
- Report
- December 2018
- 174 Pages
Global
From €1315EUR$1,375USD£1,127GBP
€2630EUR$2,750USD£2,253GBP
- Clinical Trials
- January 2022
- 60 Pages
Global
From €1434EUR$1,500USD£1,229GBP
- Clinical Trials
- January 2022
- 90 Pages
Global
From €1434EUR$1,500USD£1,229GBP
- Report
- January 2024
- 55 Pages
From €2376EUR$2,485USD£2,036GBP
€3395EUR$3,550USD£2,909GBP
- Report
- October 2018
- 32 Pages
Global
From €9562EUR$10,000USD£8,194GBP
- Drug Pipelines
- November 2020
- 78 Pages
Global
From €3347EUR$3,500USD£2,868GBP
- Report
- April 2022
- 153 Pages
Global
From €3442EUR$3,600USD£2,950GBP
- Drug Pipelines
- August 2018
- 52 Pages
Global
From €3347EUR$3,500USD£2,868GBP
- Report
- November 2021
- 747 Pages
Global
From €3825EUR$4,000USD£3,278GBP
The Proteasome Inhibitor market within the context of Oncology Drugs is a rapidly growing field of research and development. Proteasome inhibitors are drugs that target the proteasome, a cellular structure responsible for the breakdown of proteins. These drugs are used to treat a variety of cancers, including multiple myeloma, lymphoma, and other solid tumors. Proteasome inhibitors have been shown to be effective in treating these cancers, and have become an important part of the oncology drug market.
The Proteasome Inhibitor market is highly competitive, with many companies developing and marketing their own drugs. Some of the major players in the market include Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Takeda. Other companies such as Celgene, Johnson & Johnson, and AstraZeneca are also involved in the development and marketing of proteasome inhibitors. Show Less Read more